Trial Profile
Assessment of Haematological and Biochemical Effect After New Direct Acting Antiviral Drugs in Chronic Hepatitis c Virus Egyptian Patients in Assiut Province
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics
- 04 Sep 2019 Planned End Date changed from 30 Jun 2019 to 30 Jul 2020.
- 04 Sep 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2020.
- 04 Sep 2019 Status changed from not yet recruiting to active, no longer recruiting.